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Abstract Our study aimed to investigate the short-term effect
of combination antiretroviral therapy (cART) on cognitive per-
formance and functional and structural connectivity and their
relationship to plasma levels of antiretroviral (ARV) drugs.
Seventeen ARV treatment-naïve HIV-infected individuals
(baseline mean CD4 cell count, 479 ± 48 cells/mm3) were
age matched with 17 HIV-uninfected individuals. All subjects
underwent a detailed neurocognitive and functional assess-
ment and magnetic resonance imaging. HIV-infected subjects
were scanned before starting cART and 12 weeks after initia-
tion of treatment. Uninfected subjects were assessed once at
baseline. Functional connectivity (FC) was assessed within the
default mode network while structural connectivity was
assessed by voxel-wise analysis using tract-based spatial sta-
tistics (TBSS) and probabilistic tractography within the DMN.
Tenofovir and emtricitabine blood concentration were mea-
sured at week 12 of cART. Prior to cART, HIV-infected indi-
viduals had significantly lower cognitive performance than
control subjects as measured by the total Z-score from the
neuropsychological tests assessing six cognitive domains
(p = 0.020). After 12 weeks of cART treatment, there remained
only a weak cognitive difference between HIV-infected and
HIV-uninfected subjects (p = 0.057). Mean FC was lower in
HIV-infected individuals compared with those uninfected
(p = 0.008), but FC differences became non-significant after
treatment (p = 0.197). There were no differences in DTI met-
rics between HIV-infected and HIV-uninfected individuals
using the TBSS approach and limited evidence of decreased
structural connectivity within the DMN in HIV-infected indi-
viduals. Tenofovir and emtricitabine plasma concentrations did
not correlate with either cognitive performance or imaging
metrics. Conclusions: Twelve weeks of cART improves cog-
nitive performance and functional connectivity in ARV treat-
ment-naïve HIV-infected individuals with relatively preserved
immune function. Longer periods of observation are necessary
to assess whether this effect is maintained.
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Introduction
HIV infection is associated with injury of the central nervous
system (CNS) (Navia et al. 1986). The clinical manifestations
of CNS injury vary from a mild decrease in cognitive perfor-
mance without associated functional deficits to dementia
(Antinori et al. 2007). Neuroimaging biomarkers provide an
opportunity to investigate CNS injury especially at the time
when clinical changes may be small or silent (Zhu et al. 2013).
Most of the recent literature on HIV-associated cognitive im-
pairment that has included neuroimaging is derived from pa-
tient with long established HIV infection and on stable com-
bination antiretroviral treatment (cART) (Hua et al. 2013). It
has been reassuring that the cognitive deficits of those on
cART are often mild and the neuroimaging abnormalities are
limited. However, we still have limited understanding of the
causes for the persistence of cognitive impairment in HIV-
infected individuals who have been virologically suppressed
for years. One plausible explanation is that irreversible CNS
damage occurs very early in HIV infection which, when lim-
ited, causes subtle cognitive changes measurable to some de-
gree with extensive neuropsychological tests. In this case, ef-
fective cART would prevent progression of CNS injury but
not reverse previous damage (Tozzi et al. 2005). Previous
reports on cognitive improvement (not necessarily resolution)
in patients with dementia after starting cART support this pos-
sibility (Chang et al. 1999). However, it is also possible that
long-term treatment with cARTmay also induce neurotoxicity
(Robertson et al. 2010). A bimodal response could be occur-
ring where uncontrolled viral infection and associated inflam-
mation would greatly benefit from cART resulting in cogni-
tive improvement and decreased abnormalities in imaging
metrics (Chang et al. 1999). To study the early time course
progression of CNS injury in HIV infection, we focused on the
default mode network (DMN) as the major region to investi-
gate because it has been widely studied and reported to be
affected by HIV infection (Becker et al. 2013; Herting et al.
2015; Ortega et al. 2015; Thomas et al. 2013). Here, we report
our initial findings, assessing whether cognitive, functional,
and structural brain connectivity were altered prior to the ini-
tiation of cART and whether there were measurable changes
after 12 weeks of cART treatment.
Materials and methods
All subjects, who consented to participate in the study,
underwent a comprehensive clinical, laboratory (chemistry,
hematology, and urine analysis), neurocognitive, and neuro-
imaging evaluation. HIV-infected individuals were assessed
before and 12 weeks after starting cART, while HIV-
uninfected controls were assessed only at baseline.
Inclusion criteria All participants were ≥18 years of age and
antiretroviral (ARV) treatment-naïve prior to enrollment. They
met the following laboratory parameters within 30 days of
baseline evaluation: hemoglobin ≥9.0 g/dL, serum creatinine
≤2× ULN, AST (SGOT), ALT (SGPT), and alkaline phospha-
tase ≤2× upper limit of normal. Subjects were instructed to
avoid smoking and use of caffeinated drinks for at least 2 h
prior to the scheduled imaging section.
Exclusion criteria Participants with severe premorbid or co-
morbid psychiatric disorders were excluded. Subjects with
mild or stable depression including those on stable antidepres-
sant therapy were eligible for this study. Additional exclusion
criteria were stroke, head trauma resulting in loss of con-
sciousness >30 min, multiple sclerosis, brain infections (ex-
cept for HIV-1), and any space-occupying brain lesions requir-
ing acute or chronic therapy. Dementia, as established by
HAND definition (Antinori et al. 2007), was exclusionary.
Subjects meeting criteria for HIV-associated mild
neurocognitive disorder (MND) or HIV-associated asymp-
tomatic neurocognitive impairment (ANI) were eligible to
participate. Active alcohol and drug abuse (urine toxicology
was done at each visit) within 6 months of study entry and
conditions such as claustrophobia or metallic implant that
prevented MRI scanning were exclusionary.
Neuropsychological tests The neurocognitive evaluation was
performed by trained staff and supervised by a neuropsychol-
ogist and included tests of executive function (Trailmaking
Test Part B, Stroop Interference Task), speed of information
processing (Symbol Digit Modalities Test and Stroop Color
Naming), attention and working memory (CalCAP(CRT4)
and WAIS-III Letter-Number Sequencing), learning (Rey
Auditory Verbal Learning Test AVLT (trials 1–5), Rey
Complex Figure Test Immediate Recall), memory (Rey
Auditory Verbal Learning Test RAVLT Delayed Recall, Rey
Complex Figure Test Delayed Recall), and motor (Grooved
Pegboard, the left and right hands). An estimate of premorbid
intellectual functioning ability was obtained via WRAT-4
Reading. The total composite Z-score was the primary cogni-
tive outcome and was created from the linear combination of
the Z-scores of the six cognitive domains measured (executive
function, speed of information processing, attention and work-
ing memory, learning, memory, and motor). HAND diagnoses
were determined for each participant according to the Frascati
criteria (Antinori et al. 2007).
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MRI data acquisitionMRI was performed on a 3T Siemens
MAGNETOM Trio MRI scanner equipped with a 32-channel
head coil at the Rochester Center for Brain Imaging. A T1-
weighted three-dimensional magnetization-prepared rapid ac-
quisition gradient echo (MPRAGE, repetition time (TR)/in-
version time (TI)/echo time (TE) = 2530/1100/3.44 ms, voxel
s ize = 1 .0 × 1.0 × 1.0 mm3, f l ip angle = 78° ,
bandwidth = 190 Hz/pixel) was acquired. DTI scans were
acquired with the following parameters: 10 b = 0 s/mm2 im-
ages acquired increase signal to noise ratio; 60 diffusion
weighting images which uniformly distributed with
b = 1000 s/mm2; voxel size = 2 × 2 × 2 mm3; matrix
size = 128 × 128. A double-echo gradient echo field map
sequence was acquired with the same resolution as the DTI
sequence and was used to correct for distortion caused by B0
inhomogeneity (Dietrich et al. 2008). The resting-state fMRI
scans were acquired using a gradient echo-planar imaging
(EPI) sequence (TR = 2000 ms, TE = 30 ms, flip angle = 90°,
voxel size = 4 × 4 × 4 mm3; matrix size = 64 × 64, 30 axial
slices, 150 time points). During the entire 5-min resting-state
fMRI scanning, participants were instructed to keep their eyes
open and avoid falling asleep.
Resting-state fMRI processing The first ten volumes were
discarded for each subject to allow for stabilization of the
magnetic field. Standard pre-processing steps were performed
using Data Processing Assistant for Resting-State fMRI
(DPARSF) (Chao-Gan and Yu-Feng 2010) and included the
following: slice timing correction, motion correction, normal-
ization, and spatial smoothing with Gaussian kernel (full
width at half maximum (FWHM) = 4 mm), linear trend re-
moval, and band-pass filter (0.01 Hz to 0.08 Hz) to reduce the
low-frequency drift and exclude physiological noise. We used
maximum head motion displacement larger than 2 mm and
head rotation greater than 2° as exclusion criteria. No subjects
were excluded in this cohort. Each individual’s fMRI images
were normalized to Montreal Neurological Institute (MNI)
standard space. To minimize head motion effect and non-
neuronal noise, nuisance covariates including six head motion
parameters, global mean signal, white matter time series, and
CSF time series were regressed out. After pre-processing,
group independent component analysis (ICA) was performed
to identify the default mode network (DMN) using Group ICA
part of fMRI Toolbox (GIFT, http://mialab.mrn.org/software/
gift/index.html). All subjects’ resting-state fMRI data were
included in a single group ICA analysis. Data were reduced
through principal component analysis (PCA) (Calhoun et al.
2001; Erhardt et al. 2011) in two stages: one at the single
subject level and a second one at the group level. Following
data reduction, the multi-subject ICAwas performed to iden-
tify the independent component using Infomax algorithm
(Bell and Sejnowski 1995). GICA-based back-reconstruction
methods were used to reconstruct single-subject components.
This resulted in 20 independent component (IC) spatial maps
for each subject.
The single DMN component was firstly identified by visual
inspection. The one-sample t test was used to test the signifi-
cance of the selected DMN component that resulted in a t-
map. Only the posterior DMN component which includes
the posterior cingulate cortex (PCC) and the inferior parietal
cortex (IPC) were included after using p < 0.0001 with FDR
correction.
The average time series of all the voxels in the DMN was
calculated and correlated with each voxel’s own time series
within DMN, to calculate within-network functional connec-
tivity (Supekar et al. 2010). Fisher’s r-to-z transformation was
applied to the functional connectivity for each individual.
Diffusion tensor imaging processing
The first ten b = 0 images and 60 diffusion-weighted images
were firstly corrected for motion and eddy-current-induced
distortion, using eddy correct tool in FSL (Smith et al. 2004;
Woolrich et al. 2009; Jenkinson et al. 2012). The ten b = 0
images were averaged as a b0 image, which was then used to
register DTI data to T1 structural image using boundary-based
registration (BBR) (Greve and Fischl 2009) in FSL. Brain
extraction was performed on the averaged b0 image using
BET (Smith 2002) in FSL. The averaged b0 image and 60
DWIs were used to calculate the tensor-derived scalar metrics
including fractional anisotropy (FA), mean diffusivity (MD),
radial diffusivity (RD), and axial diffusivity (AD) using
DTIFIT in FSL. A brain mask was applied on each tensor-
derived scalar metric to create brain-extracted maps.
Voxel-wise analysis was performed using tract-based spa-
tial statistics (TBSS) (Smith et al. 2006), part of FSL. Group
comparisons were performed using the Randomize toolbox
(Nichols and Holmes 2002; Winkler et al. 2014) in FSL, and
the threshold-free cluster enhancement (TFCE) approach
(Smith and Nichols 2009) was used for multiple comparison
correction. We also performed probabilistic tractography
within DMN using FSL. ADMNmaskwas manually selected
from Group ICA analysis using resting-state fMRI: PCC
served as seed region, and medial prefrontal cortex (mPFC),
left- and right-inferior parietal cortex (IPC) served as target
regions, respectively. The structural connectivity (SC) was
calculated in two ways, the total number of voxel within the
tracts, and the mean FA within the tracts. (See Supplemental
material for details).
Drug concentration measurement and pharmacokinetic
analysis
Plasma tenofovir (TFV) and emtricitabine (FTC) were mea-
sured using a newly developed and validated liquid
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chromatography with tandem mass spectrometry (LC-MS/
MS) method (Delahunty et al. 2009). TFV and FTC were
chromatographically separated on the LC system, detected at
the tandem MS system and calibrated within a linear range of
10–1000 ng/mL. The lower limit of quantitation for TFVand
FTC was determined to be 10.0 ng/mL, and assay precision
was <10%. The study participants were taking ARV regimens
that included tenofovir disoproxil fumarate (TDF) 300 mg
daily and FTC 200 mg daily for at least 12 weeks. In order
to estimate TFV and FTC exposure, population models were
developed using the data from the AIDS Clinical Trials Group
study A5202 (Beal 2001; Sax et al. 2009; Valade et al. 2014).
TFV and FTC pharmacokinetics at the steady state was best
described by a two-compartment linear mammillary model
with first-order absorption with inter-individual variability
on clearance. The exposure was indicated by the area under
the plasma drug concentration-time curve (AUC, mg/L*h).
Statistical analysis
Data are presented as mean ± SE throughout this manuscript.
Comparisons between two independent groups were subject-
ed to Wilcoxon rank-sum test. For comparing measurements
collected from the same subject at two time points, Wilcoxon
signed-rank test was used instead. Spearman correlation test
was used for testing the dependence of two continuous vari-
ables. A p value <0.05 was considered statistically significant.
All analyses were performed in R 3.2.0 (R Foundation for
Statistical Computing, Vienna, Austria) and in SAS 9.3 (SAS
Institute, Cary NC).
Results
Seventeen ARV treatment-naïve HIV-infected individuals
were age matched with 17 HIV-uninfected individuals. HIV-
infected individuals were scanned before starting cART, and,
on average, 12 weeks after the initiation of ARV treatment.
Demographics and baseline clinical characteristics are shown
in Table 1. The groups were well balanced for age and educa-
tion. The uninfected group was more likely to be female and
White. At baseline, ten HIV-infected individuals had normal
cognitive performance, six had ANI, and one had MND.
ApplyingHAND classification toHIV-uninfected individuals,
there was a similar proportion of cognitive impairment.
However, when using the composite Z-score of all cognitive
tests, HIV-infected individuals performed worse than HIV-
uninfected individuals (Table 2). The mean CD4 cell count
and HIV RNA levels at baseline were 479 ± 48 cells/mm3
and 5.08 ± 4.64 log10 copies/mL, respectively. The relatively
high CD4 cell count in the HIV-infected individuals at base-
line likely reflects a recent HIV infection; however, timing
from exposure to HIV to diagnosis was not available. After
12 weeks, mean CD4 cell count and HIV RNA levels were
636 ± 55 cells/mm3 and 899 ± 861 copies/mL, respectively.
Antiretroviral regimens prescribed included Complera
(rilpivirine, FTC, TDF, n = 2), Stribild (elvitegravir, cobicistat,
FTC, TDF, n = 8), Atripla (efavirenz, FTC, TDF, n = 3),
Truvada (FTC/TDF) plus Tivicay (dolutegravir, n = 1),
Truvada (FTC/TDF) plus Isentress (raltegravir, n = 1), and
Triumeq (dolutegravir, abacavir, lamivudine, n = 1).
The results in Table 2 show that the mild cognitive deficits
present at baseline in HIV-infected compared with HIV-
uninfected individuals, tended to improve in most cognitive
domains, with exception of motor function, after 12 weeks of
cART.
Functional connectivity (FC) was evaluated within the
DMN. For these analyses, 16 HIV-infected and 16 HIV-
uninfected individuals were available at baseline and 14
HIV-infected individuals at 12 weeks. Mean FC at baseline
was 0.588 in HIV-infected and 0.689 in those uninfected (p
value = 0.008). After 12 weeks of cART, mean FC increased
to 0.637, and when compared with HIV-uninfected individ-
uals, the difference was not significant (p value = 0.197).
Figure 1 shows the DMN in this population as determined
using ICA and the mean FC in the DMN for each group of
subjects and visits.
We further examined the relationship between FC and cog-
nitive performance. FC was significantly correlated with total
Z-score in HIV-infected individuals at baseline (Spearman
correlation 0.50, p value = 0.046) (see Fig. 2) but was not
significantly correlated with either HIV-infected after
12 weeks of cART or HIV uninfected. Other variables such
as CD4 cell count, HIV RNA levels, and the duration of HIV
infection were not significantly correlated with FC (Fig. 3).
We also assessed whether the FC and total Z-score corre-
lated with plasma exposure of TFV and FTC. For both TFV
and FTC, there was no significant correlation between FC and
plasma exposure (p value = 0.73 and 0.26, respectively) and
Z-score and plasma exposure of these ARVs (p value = 0.58
and 0.51, respectively).
White matter microstructure abnormalities were assessed
via diffusion tensor imaging and specifically via TBSS and
probabilistic tractography within the DMN. No significant
differences were found in TBSS analyses between HIV-
infected and HIV-uninfected individuals nor in HIV-infected
individuals before and after 12 weeks of cART. However, the
results from the probabilistic tractography were inconclusive.
While the total number of voxels from PCC to left-IPC was
significantly greater in HIV-uninfected compared with HIV-
infected both at baseline and 12 weeks of treatment, p < 0.01
and p < 0.05, respectively, the mean FA within the tract was
not significant. In addition, we did not find significant differ-
ences in the other two pairs of tracts, in either number of
voxels or mean FA. Lastly, there was no significant correlation
between SC and FC.
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Discussion
There is still ongoing debate onwhether long-term use of cART
may have deleterious effect on brain structure and function
(Robertson et al. 2010; Cysique et al. 2009; Smurzynski et al.
2011;Marra et al. 2009). Neuroimaging has been used as a non-
invasive tool to assess CNS injury in HIV-infected individuals.
A few studies have assessed the impact of HIV infection and
cART on cognitive performance and imaging metrics using
fMRI or diffusion tensor imaging in ARV treatment-naïve in-
dividuals in a cross-sectional design (Ortega et al. 2015; Chang
et al. 2008; Ragin et al. 2015). Our study adds to this literature
by evaluating a longitudinal design and ARV regimens that
reflects current standard of practice in the USA. We found
significant differences in cognitive performance, as measured
by the total composite Z-score created from combination of all
neuropsychological tests used, and functional connectivity (FC)
within DMN in ARV treatment-naïve HIV-infected compared
with HIV-uninfected individuals that improved after 12 weeks
of cART. Of note, neither baseline HIV RNA levels nor CD4
cell count correlated with either FC or cognitive performance.
A recent cross-sectional study by Ortega et al. (2015) ana-
lyzed cognitive performance and FC in three groups of individ-
uals: HIV-uninfected, HIV-infected on cART, and HIV-infected
not on cART. The group not on cART was a mix of never on
cART or currently not taking cART. The investigators found
that HIV-infected individuals had lower FC than HIV-
uninfected individuals in areas that included DMN, and this
Table 2 Cognitive performance by composite Z-score cognitive domain at baseline in HIV-uninfected individuals and in HIV-infected individuals
before and after 12 weeks on cART
Composite Z-score HIV− baseline
(mean ± SE)
HIV+ baseline
(mean ± SE)
HIV+ 12 weeks
(mean ± SE)
HIV− vs. baseline
HIV+ (p value)a
HIV+ 12 weeks vs.
HIV− (p value)a
HIV+ baseline vs.
12 weeks (p value)b
Executive function 0.30 ± 0.28 −0.24 ± 0.23 −0.06 ± 0.21 0.125 0.379 0.332
Speed of
information
processing
0.33 ± 0.21 −0.13 ± 0.25 −0.20 ± 0.26 0.179 0.158 1.000
Attention 0.21 ± 0.22 −0.23 ± 0.27 0.02 ± 0.23 0.343 0.617 0.309
Learning 0.09 ± 0.22 −0.13 ± 0.22 0.04 ± 0.29 0.502 0.667 0.404
Memory 0.00 ± 0.22 −0.12 ± 0.24 0.11 ± 0.27 0.730 0.654 0.094
Motor 0.53 ± 0.22 −0.29 ± 0.26 −0.24 ± 0.21 0.023 0.025 0.624
Total composite
Z-score
1.46 ± 0.86 −1.14 ± 1.07 −0.32 ± 0.9 0.020 0.057 0.174
aWilcoxon rank-sum test
bWilcoxon signed-rank test
p-value < 0.05 were in italics
Table 1 Demographics and
baseline clinical variables HIV infected (n = 17) HIV uninfected (n = 17) p value
Age ((years) mean ± SE) 32.6 ± 2.9 32.4 ± 3.0 0.956
Gender (M:F) 17:0 7:10 <0.001
Ethnicity (White:Black:other) 8:9:0 12:3:2 0.042
Education
≤12 years 4 3 1
>12 years 13 14
HIV duration by patient report
at baseline ((months) median (range))
1 (1, 120) NA –
Baseline CD4 cell count
((cells/mm3) mean ± SE)
479.2 ± 48.5 NA –
Baseline HIV RNA levels
((log10 unit) median (range))
4.7 (1.7, 5.8) NA –
HAND classification at baseline
Normal 10 11 1
ANI 6 5
MND 1 1
HAND HIV-Associated Neurocognitive Disorder, ANI Asymptomatic Neurocognitive Impairment, MND Mild
Neurocognitive Disorder
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was even lower in those not on cART. Our results confirm these
findings and provide longitudinal support that ARV treatment,
at least in the short run, tends to normalize the FC. Importantly,
we also show that cognitive performance correlated with FC
before ARV treatment and that after treatment, improvement in
cognitive performance rendered this correlation non-significant,
similar to the observation in HIV-uninfected individuals.
While several studies have found some difference in FC,
not necessarily in the same networks, between HIV-infected
and HIV-uninfected individuals (Ortega et al. 2015; Thomas
et al. 2013; Ipser et al. 2015; Wang et al. 2011), others have
not (Janssen et al. 2016). However, these studies represent
heterogeneous populations and analysis methods and thus
are difficult to compare. Another study, for example, using a
fMRI activation task, found that HIV-infected individuals on
cART require greater brain activation than HIV-infected not
on cART or HIV-uninfected, thus pointing to a possible dele-
terious effect of cART (Chang et al. 2008).
We and others have shown that HIV infection is associated
with microstructural white matter abnormalities (Zhu et al.
2013; Ragin et al. 2005; Pfefferbaum et al. 2007; Pomara
et al. 2001). These studies have included HIV-infected indi-
viduals with different degrees of immune suppression and
comorbidities. The current study offers the opportunity to as-
sess the effect of HIV viremia and cART on white matter in a
longitudinal design in ARV treatment-naïve subjects with rel-
ative preserved immune function, comparing them very well
with age-matched HIV-uninfected controls. We found no sig-
nificant white matter microstructural differences (using
TBSS) comparing HIV-infected with HIV-uninfected and
HIV-infected before and after starting cART. These results
differ from a recent cross-sectional study in patients recently
infected, which found abnormalities in the corpus callosum
Fig. 1 Functional connectivity
(FC) within default mode
network (DMN). Mean FC for
HIV infected before treatment
was 0.588 and increased to 0.637
after 12 weeks of cART, while the
mean FC for HIV-uninfected
group was 0.689; *p = 0.008
Fig. 2 Functional connectivity correlation with cognitive performance.
FC was significantly correlated with total composite Z-score for HIV-
infected individuals at baseline (ρ = 0.50, p value = 0.046) but not with
HIV-uninfected individuals
J. Neurovirol. (2017) 23:704–712 709
(Ragin et al. 2015). One possible explanation is that the pa-
tients in our study had a relatively well-preserved immune
function and both HIV-infected and HIV-uninfected individ-
uals were tightly age matched. Group differences in gender, as
observed in our study, are less likely to affect DTI metrics
while age has a large impact (Wu et al. 2011). Given the small
sample size, variability in immune function and age may have
a large effect on results.
In order to more directly compare functional and structural
connectivity, we assessed structural connectivity within the
DMN using probabilistic tractography. The results of these
analyses were inconclusive as we found decreased connectiv-
ity, when measured by number of voxel, in HIV-infected in-
dividuals only in the tract connecting PCC to left IPC.
However, mean FA within this tract, the PCC to right IPC,
and PCC to medial prefrontal cingulate cortex did not differ
between HIV-infected and HIV-uninfected individuals.
We did not find a significant correlation between the plas-
ma exposures of TFV and FTC with both cognitive perfor-
mance and FC. These results do not exclude potential long-
term effect as suggested by a recent small study (Ma et al.
2015) where higher plasma concentrations of TFV and FTC
were found in patients with declining cognitive performance.
The distribution of these agents into the brain, particularly
TFV, is limited due to its anionic charge at physiological pH
making it difficult to cross the blood–brain barrier. In fact, low
TFV concentrations and accordingly high HIV RNA levels in
cerebral spinal fluid (CSF) were reported in previous studies
suggesting the CNS as a sanctuary for HIV viral replication
and viral escape (Best et al. 2012; Calcagno et al. 2011).
Limitations in this study include small sample and short
duration of the longitudinal follow-up. In addition, gender
and ethnicity was significantly different in the two cohorts.
However, these factors should have not significantly affected
the neuroimaging results (Joel et al. 2015). Also, we cannot
exclude that cognitive performance improved in the HIV-
infected individuals secondary to a practice effect. The study
design did not include a 12-week evaluation in the HIV-
uninfected group as we did not expect cognition to change
within that period. However, the change observed in FC in
HIV-infected individuals is unlikely to be explained by prac-
tice effect.
In summary, our results suggest that in fairly young ARV
treatment-naïve individuals with relatively preserved immune
function, there are signs of decreased functional connectivity
that correlates with decreased cognitive performance. There
was inconclusive evidence of white matter microstructural
abnormalities suggesting that the process may be reversible
Fig. 3 Correlations between
plasma exposure of TFV, FTC,
and FC and cognitive
performance
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if HIV infection is treated early. In this regard, the improve-
ment in cognitive performance and FC after 12 weeks of
cART is encouraging and would favor the current approach
of treating HIV infection as early as possible. However, a
longer longitudinal follow-up and larger study is necessary
to assess whether the improvement observed is sustainable
overtime or whether the potential neurotoxicity of cART will
manifest.
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